Tinlarebant - Belite Bio
Alternative Names: aka LBS-008; BPN-14967; LBS-008Latest Information Update: 11 Mar 2026
At a glance
- Originator Columbia University
- Developer Belite Bio
- Class Eye disorder therapies; Fluorinated hydrocarbons; Ketones; Piperidines; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action RBP4 protein inhibitors
-
Orphan Drug Status
Yes - Stargardt disease
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dry macular degeneration; Stargardt disease
Most Recent Events
- 02 Mar 2026 Belite Bio announces intention to submit NDA to the PMDA for Stargardt disease
- 02 Mar 2026 Belite Bio announces intention to submit NDA to the US FDA for Stargardt disease in the second quarter of 2026
- 27 Jan 2026 Belite Bio completes enrolment in its phase II/III DRAGON II trial for Stargardt disease (In adolescents, In adults) in Japan, the US, and the United Kingdom (PO) (NCT0638808)